Skip to main content

Lichen Sclerosus

Lichen sclerosus (LS) is a chronic inflammatory mucocutaneous dermatosis that preferentially affects the anogenital skin. It produces ivory-white, atrophic, sclerotic plaques with itching, soreness, fissuring, scarring, sexual dysfunction, urinary morbidity, and increased risk of squamous cell carcinoma.[1][2][3]

For the reconstructive urologist and urogynecologist, LS is not just a dermatologic diagnosis. It determines whether penile skin can be used for urethroplasty, explains meatal stenosis and long penile strictures, causes phimosis and buried-penis inflammatory scarring, narrows the vulvar introitus, buries the clitoris, and creates a lifelong cancer-surveillance obligation.

Definition and Terminology​

TermMeaning
Lichen sclerosus (LS)Current preferred term
Lichen sclerosus et atrophicus (LSA)Historical term; "et atrophicus" is usually dropped
Balanitis xerotica obliterans (BXO)Historical male genital term, especially for glans/prepuce disease
Kraurosis vulvaeObsolete term for vulvar LS

LS is usually anogenital, but extragenital disease occurs. Vaginal mucosa is classically spared; vulvar, perineal, perianal, penile, preputial, glanular, and meatal skin are the reconstructively important territories.[1][4][5]

Epidemiology​

LS is underdiagnosed. Population estimates vary by specialty, biopsy practice, and registry capture.[1][5][6]

Key patterns:

  • Female predominance is typical, often quoted around 6:1 to 10:1.
  • Bimodal female age pattern: prepubertal girls and postmenopausal women.
  • Male disease commonly presents as phimosis, glans/preputial plaques, meatal stenosis, or urethral stricture.
  • Children may present with vulvar symptoms, constipation from painful fissures, or phimosis/BXO in boys.[1][7][8]

Recent registry studies suggest LS incidence is rising, likely reflecting both true recognition and improved diagnostic coding. A Swedish nationwide register study reported incidence in both females and males, while Danish biopsy-verified vulvar LS data showed a marked rise in incidence from 1997 to 2022 and increased vulvar precancer/cancer risk.[6][9]

Etiology and Pathophysiology​

The cause is incompletely understood. LS likely represents an immune-mediated disease in genetically susceptible skin, modified by trauma, hormonal milieu, local inflammation, and oxidative stress.[1][10][11]

Immune and Genetic Factors​

  • Autoimmune disease is common, especially thyroid disease, alopecia areata, vitiligo, and pernicious anemia.
  • Circulating autoantibodies and reactivity against extracellular matrix protein 1 (ECM1) have been reported.
  • T-cell mediated inflammation, Th1/IFN-gamma pathways, tissue-remodeling genes, and microRNA changes are implicated.
  • Familial clustering and HLA associations support genetic susceptibility.[1][10]

Hormonal and Local Factors​

Prepubertal and postmenopausal peaks suggest a role for hypoestrogenic tissue vulnerability, but estrogen deficiency alone does not explain LS. Premenopausal women and adult men can develop active disease.[1][2]

Koebner Phenomenon​

LS can appear in areas of trauma, chronic irritation, surgical scars, urine exposure, and friction. This matters after circumcision, vulvar surgery, urethroplasty, buried penis repair, and graft/flap reconstruction: trauma can unmask or reactivate disease in susceptible tissue.[1][5][11]

Infection​

Infectious triggers such as Borrelia burgdorferi have been proposed but remain unproven. LS should not be treated as an infectious disease.[5][11]

Clinical Presentation​

Symptoms​

Common symptoms include:

  • Pruritus
  • Burning, soreness, fissuring, or pain
  • Dyspareunia
  • Dysuria or urine stinging over fissures
  • Painful defecation or constipation in children with perianal disease
  • Painful erections, phimosis, spraying, weak stream, or obstructive voiding in male genital/meatal disease
  • Asymptomatic white plaques discovered on exam[1][5][12]

Classic Signs​

SiteFindings
Vulva / perineum / perianal skinPorcelain-white plaques, "cigarette paper" atrophy, fissures, purpura/ecchymoses, figure-eight/hourglass distribution
Female architectureLabia minora resorption, labial fusion, clitoral phimosis, introital narrowing, posterior fourchette fissures
Penis / foreskin / glansWhite sclerotic plaques, phimotic ring, adhesions, glans atrophy, coronal sulcus obliteration, meatal stenosis
UrethraMeatal stenosis, fossa navicularis disease, penile urethral stricture, panurethral extension in severe cases
Extragenital skinIvory-white plaques on trunk, breasts, thighs, or other sites; often less symptomatic

In pediatric girls, vulvar bruising, fissuring, and bleeding can be mistaken for sexual abuse. LS does not exclude abuse when the history or injury pattern is concerning, but recognizing the characteristic pattern prevents unnecessary harm.[1][13]

Histopathology​

Classic histology includes:

  • Epidermal atrophy with flattening/loss of rete ridges
  • Hyperkeratosis, sometimes with follicular plugging
  • Vacuolar interface dermatitis with basal layer injury
  • Homogenized, hyalinized superficial dermal collagen
  • Band-like lymphocytic infiltrate beneath the sclerotic zone
  • Loss of elastic fibers in the papillary dermis[14][15][16]

Early or hypertrophic LS may be histologically subtle. Minimal useful clues are a vacuolar interface reaction plus any thickness of dermal sclerosis separating inflammation from epithelium.[15][16]

Diagnosis​

Diagnosis is usually clinical when classic anogenital plaques, fissuring, and scarring are present. Biopsy is indicated when the diagnosis is uncertain, disease is atypical, there is treatment failure, or malignancy is a concern.[5][17]

Biopsy suspicious areas:

  • New pigmentation
  • Induration or fixation to underlying tissue
  • Hyperkeratotic, verrucous, bleeding, ulcerated, or nonhealing lesion
  • Rapid change
  • Persistent erosion despite adequate steroid therapy
  • Immunocompromised patient
  • Any lesion where SCC, differentiated VIN, penile intraepithelial neoplasia, or vulvar intraepithelial neoplasia is plausible[17][18]

Differential Diagnosis​

DiagnosisDistinguishing features
Lichen planusErosive vestibular/vaginal involvement, Wickham striae, oral disease
Lichen simplex chronicusThickened lichenified skin from itch-scratch cycle
VitiligoDepigmentation without sclerosis, fissuring, or scarring
MorpheaExtragenital/localized scleroderma pattern; less mucosal/genital predilection
Psoriasis / dermatitisErythematous plaques, scale, irritant/contact history
Genitourinary syndrome of menopauseAtrophy and dyspareunia without classic white sclerotic plaques
VIN / penile intraepithelial neoplasia / SCCFocal hyperkeratosis, ulcer, induration, pigmentation, bleeding, mass

Treatment​

First-Line: High-Potency Topical Corticosteroids​

High-potency topical corticosteroids are first-line therapy for genital LS. Clobetasol propionate 0.05% ointment is the most common induction agent.[5][17][19][20]

Common vulvar induction pattern:

  • Apply clobetasol 0.05% ointment daily or twice daily during active disease.
  • Continue induction for roughly 6-12 weeks depending on severity and local protocol.
  • Taper to maintenance once symptoms and signs improve.
  • Continue long-term maintenance, often 1-2 times weekly, individualized to disease control.

Ointment is preferred to cream because it stings less and supports barrier function. The goal is not only itch relief; it is prevention of scarring and cancer-risk reduction through durable inflammation control.[5][19][21]

When used correctly, topical corticosteroids are safe for long-term genital LS. Undertreatment from steroid fear is more dangerous than appropriately monitored maintenance therapy.

Topical Calcineurin Inhibitors​

Tacrolimus or pimecrolimus can be considered when corticosteroids fail, are not tolerated, or are contraindicated. They may reduce symptoms, but clobetasol is generally superior for clinical remission and architectural control.[20][22][23]

Refractory Disease​

Refractory LS should trigger reassessment before escalating:

  • Is the diagnosis correct?
  • Is medication being applied to the right location and in the right quantity?
  • Is there contact dermatitis, candidiasis, GSM, lichen planus, psoriasis, or neuropathic pain?
  • Is there hidden dVIN/SCC?
  • Is scarring rather than active inflammation driving symptoms?

Options for refractory inflammatory disease include intralesional triamcinolone, alternate potent steroids, topical calcineurin inhibitors, specialist dermatology/vulvar clinic referral, and selected systemic or procedural therapies in rare cases.[1][5][24]

Surgery​

Surgery treats complications, not the inflammatory disease itself.

SettingOperation
Male phimosis from LSCircumcision with complete removal of diseased foreskin when medical therapy fails
Meatal stenosisMeatotomy or meatoplasty plus ongoing topical therapy
LS urethral strictureOral mucosal graft urethroplasty, staged repair, perineal urethrostomy, or diversion based on extent and patient goals
Clitoral phimosisClitoral hood release / unhooding for trapped keratin, pain, sexual dysfunction
Introital stenosis or labial fusionAdhesiolysis, scar release, introital reconstruction, postoperative steroid and dilation when appropriate
CancerOncologic excision, staging, and multidisciplinary care

Circumcision can be curative for isolated foreskin disease but not for meatal or urethral involvement.[7][25][26]

Urological and Reconstructive Complications​

Male Genital LS​

Male LS can involve the foreskin, glans, meatus, fossa navicularis, and anterior urethra. Urologic consequences include:

  • Pathologic phimosis
  • Glans/preputial adhesions
  • Meatal stenosis
  • Penile urethral stricture
  • Panurethral stricture
  • Painful erections
  • Spraying, weak stream, retention, recurrent UTI
  • Penile SCC risk[7][11][25][27]

LS Urethral Stricture​

LS-related strictures are often distal, penile, long, recurrent, and more complex than iatrogenic bulbar strictures. The key reconstructive rule is:

Do not use genital skin as graft or flap material in LS-associated urethral reconstruction.

The AUA urethral stricture guideline emphasizes avoiding genital skin flaps/grafts in LS strictures and reconstructing according to anterior urethroplasty principles. Oral mucosa is the preferred substitution tissue.[28][29]

Severe disease may require staged oral mucosal graft urethroplasty, perineal urethrostomy, or urinary diversion when tissue quality, length, recurrence, comorbidity, or patient preference make reconstruction unreasonable.

Female Urologic Complications​

Female LS can contribute to dysuria, urine stinging, introital stenosis, dyspareunia, clitoral phimosis, recurrent fissuring, and rarely urethral narrowing. When female voiding symptoms coexist with LS, do not assume all symptoms are dermatologic: assess for urethral stricture, pelvic floor dysfunction, GSM, recurrent UTI, and pain syndromes.[28]

Malignancy Risk​

LS increases risk of anogenital squamous cell carcinoma. In women, the key pathway is HPV-independent vulvar carcinogenesis through differentiated VIN and p53-abnormal lesions. In men, LS is associated with increased penile SCC risk.[9][18][30][31]

Practical risk framing:

  • Vulvar SCC lifetime risk is often quoted around 4-5% in women with LS.
  • Danish data show increased risk of vulvar high-grade squamous precancer and SCC in biopsy-verified vulvar LS.[9]
  • Swedish registry data show increased vulvar cancer risk among patients with LS.[6]
  • Male absolute penile cancer risk is low, but relative risk is increased.[32]
  • Persistent inflammation, undertreatment, older age, long disease duration, and coexistent dVIN raise concern.[18][30][33]

Long-term topical corticosteroid adherence may reduce malignant transformation risk by suppressing inflammation.[5][33]

Pediatric LS​

Girls​

Symptoms include vulvar itching, soreness, dysuria, constipation from painful fissures, bleeding, and perianal discomfort. Findings can mimic trauma or sexual abuse, especially bruising, fissures, and bleeding.[1][13][34]

Treatment is still topical corticosteroid based. Pediatric series support ultrapotent topical corticosteroids with good symptom response and low serious adverse-event rates when properly supervised.[34][35][36]

Boys​

Male pediatric LS commonly presents as BXO with pathologic phimosis, foreskin whitening, fissuring, ballooning, glans involvement, or meatal stenosis. Topical steroids may help early disease, but circumcision is often definitive for foreskin-limited LS and should remove diseased preputial tissue completely.[7][25]

Children require follow-up because relapse can occur and scarring may not reverse once established.

Surveillance and Long-Term Management​

LS is chronic. Management goals are:

  • Control itch, pain, fissures, and inflammation
  • Preserve vulvar/penile architecture
  • Prevent phimosis, meatal stenosis, urethral stricture, and introital stenosis
  • Maintain sexual and urinary function
  • Detect dVIN, penile/vulvar intraepithelial neoplasia, and SCC early

Follow-up is typically every 3-6 months during induction or unstable disease, then at least annually when stable; many vulvar specialists maintain 6- to 12-month surveillance indefinitely. Biopsy any changing, thickened, ulcerated, bleeding, pigmented, or treatment-resistant lesion.[5][17][19]

Patients should be taught lifelong self-examination and shown exactly where to apply medication. "Use clobetasol" is not enough; treatment failure is often an application-map problem.

See Also​

References​

1. De Luca DA, Papara C, Vorobyev A, et al. "Lichen sclerosus: the 2023 update." Frontiers in Medicine. 2023;10:1106318. doi:10.3389/fmed.2023.1106318

2. Powell JJ, Wojnarowska F. "Lichen sclerosus." Lancet. 1999;353(9166):1777-1783. doi:10.1016/S0140-6736(98)08228-2

3. Kirtschig G. "Lichen sclerosus-presentation, diagnosis and management." Deutsches Arzteblatt International. 2016;113(19):337-343. doi:10.3238/arztebl.2016.0337

4. Ringel NE, Iglesia C. "Common benign chronic vulvar disorders." American Family Physician. 2020;102(9):550-557.

5. Kirtschig G, Woelber L, Günthert A, et al. "Evidence- and consensus-based guideline on lichen sclerosus." Journal der Deutschen Dermatologischen Gesellschaft. 2026;24(4):566-584. doi:10.1111/ddg.70000

6. Jerkovic Gulin S, Lundin F, Eriksson O, Seifert O. "Lichen sclerosus-incidence and comorbidity: a nationwide Swedish register study." Journal of Clinical Medicine. 2024;13(10):2761. doi:10.3390/jcm13102761

7. Nguyen ATM, Holland AJA. "Balanitis xerotica obliterans: an update for clinicians." European Journal of Pediatrics. 2020;179(1):9-16. doi:10.1007/s00431-019-03516-3

8. Conte S, Mohamed SD, Cohen Y, et al. "Clinical presentations and complications of lichen sclerosus: a systematic review." Journal der Deutschen Dermatologischen Gesellschaft. 2025;23(2):143-149. doi:10.1111/ddg.15606

9. Baandrup L, Hannibal CG, Hertzum-Larsen R, Kjaer SK. "Biopsy-verified vulvar lichen sclerosus: incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma." International Journal of Cancer. 2024;155(3):501-507. doi:10.1002/ijc.34927

10. Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. "Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets." International Journal of Biological Sciences. 2019;15(7):1429-1439. doi:10.7150/ijbs.34613

11. Fergus KB, Lee AW, Baradaran N, et al. "Pathophysiology, clinical manifestations, and treatment of lichen sclerosus: a systematic review." Urology. 2020;135:11-19. doi:10.1016/j.urology.2019.09.034

12. Pérez-López FR, Vieira-Baptista P. "Lichen sclerosus in women: a review." Climacteric. 2017;20(4):339-347. doi:10.1080/13697137.2017.1343295

13. Morrel B, Ewing-Graham PC, van der Avoort IAM, Pasmans SGMA, Damman J. "Structured analysis of histopathological characteristics of vulvar lichen sclerosus in a juvenile population." Human Pathology. 2020;106:23-31. doi:10.1016/j.humpath.2020.09.003

14. Leoni E, Kempf W, Cerroni L. "Lichen sclerosus et atrophicus with histopathologic features mimicking mycosis fungoides: a large series of cases comparing genital with extragenital lichen sclerosus." The American Journal of Surgical Pathology. 2022;46(1):83-88. doi:10.1097/PAS.0000000000001738

15. Yadav D, Agarwal S, Thakur S, Ramam M. "Lymphocyte-peppered sclerotic collagen: an additional histological clue in lichen sclerosus, morphea, and systemic sclerosis." The American Journal of Dermatopathology. 2021;43(12):935-938. doi:10.1097/DAD.0000000000002071

16. Carlson JA, Lamb P, Malfetano J, Ambros RA, Mihm MC. "Clinicopathologic comparison of vulvar and extragenital lichen sclerosus: histologic variants, evolving lesions, and etiology of 141 cases." Modern Pathology. 1998;11(9):844-854.

17. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin Summary, Number 224." Obstetrics & Gynecology. 2020;136(1):222-225. doi:10.1097/AOG.0000000000003945

18. Spekreijse JJ, Streng BMM, Vermeulen RFM, et al. "The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: a systematic review." Gynecologic Oncology. 2020;157(3):671-677. doi:10.1016/j.ygyno.2020.02.020

19. Chi CC, Kirtschig G, Baldo M, et al. "Topical interventions for genital lichen sclerosus." Cochrane Database of Systematic Reviews. 2011;(12):CD008240. doi:10.1002/14651858.CD008240.pub2

20. Funaro D, Lovett A, Leroux N, Powell J. "A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus." Journal of the American Academy of Dermatology. 2014;71(1):84-91. doi:10.1016/j.jaad.2014.02.019

21. Casey GA, Cooper SM, Powell JJ. "Treatment of vulvar lichen sclerosus with topical corticosteroids in children: a study of 72 children." Clinical and Experimental Dermatology. 2015;40(3):289-292. doi:10.1111/ced.12519

22. Pergialiotis V, Bellos I, Biliou EC, et al. "An arm-based network meta-analysis on treatments for vulvar lichen sclerosus and a call for development of core outcome sets." American Journal of Obstetrics and Gynecology. 2020;222(6):542-550.e6. doi:10.1016/j.ajog.2019.10.095

23. Chi CC, Kirtschig G, Baldo M, et al. "Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus." Journal of the American Academy of Dermatology. 2012;67(2):305-312. doi:10.1016/j.jaad.2012.02.044

24. Borghi A, Corazza M. "Novel therapeutic approaches and targets for treatment of vulvar lichen sclerosus." Current Pharmaceutical Biotechnology. 2021;22(1):99-114. doi:10.2174/1389201021666200516154310

25. Kravvas G, Shim TN, Doiron PR, et al. "The diagnosis and management of male genital lichen sclerosus: a retrospective review of 301 patients." Journal of the European Academy of Dermatology and Venereology. 2018;32(1):91-95. doi:10.1111/jdv.14488

26. Shieh C, Hakam N, Pearce RJ, et al. "Conservative management of penile and urethral lichen sclerosus: a systematic review." The Journal of Urology. 2024;211(3):354-363. doi:10.1097/JU.0000000000003804

27. Kantere D, Alvergren G, Gillstedt M, Pujol-Calderon F, Tunbäck P. "Clinical features, complications and autoimmunity in male lichen sclerosus." Acta Dermato-Venereologica. 2017;97(3):365-369. doi:10.2340/00015555-2537

28. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. "Urethral stricture disease guideline amendment (2023)." The Journal of Urology. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482

29. Chung ASJ, Suarez OA. "Current treatment of lichen sclerosus and stricture." World Journal of Urology. 2020;38(12):3061-3067. doi:10.1007/s00345-019-03030-z

30. Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J. "Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma." Cancer Epidemiology, Biomarkers & Prevention. 2016;25(8):1224-1230. doi:10.1158/1055-9965.EPI-16-0019

31. Steinkasserer L, Hachenberg J, Hillemanns P, Jentschke M. "Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis." Archives of Gynecology and Obstetrics. 2023;307(6):1921-1928. doi:10.1007/s00404-022-06848-y

32. Staerk MG, Kaderly Rasmussen EL, Hannibal CG, et al. "Histologically verified penile lichen sclerosus-incidence in Denmark over 26 years and long-term risk of penile and non-penile cancer." International Journal of Cancer. 2025. doi:10.1002/ijc.35454

33. Lee A, Bradford J, Fischer G. "Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women." JAMA Dermatology. 2015;151(10):1061-1067. doi:10.1001/jamadermatol.2015.0643

34. Nerantzoulis I, Grigoriadis T, Michala L. "Genital lichen sclerosus in childhood and adolescence-a retrospective case series of 15 patients: early diagnosis is crucial to avoid long-term sequelae." European Journal of Pediatrics. 2017;176(10):1429-1432. doi:10.1007/s00431-017-3004-y

35. Boero V, Caia C, Mastrangelo M, et al. "Pediatric vulvar lichen sclerosus: is a one-size-fits-all prolonged induction therapeutic regimen effective? A referral center experience." Journal of Pediatric and Adolescent Gynecology. 2026;39(2):178-183. doi:10.1016/j.jpag.2025.12.005

36. Smith SD, Fischer G. "Childhood onset vulvar lichen sclerosus does not resolve at puberty: a prospective case series." Pediatric Dermatology. 2009;26(6):725-729. doi:10.1111/j.1525-1470.2009.01022.x